Diabetes cell therapies take evasive action
Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2022-03, Vol.40 (3), p.291-295 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 295 |
|---|---|
| container_issue | 3 |
| container_start_page | 291 |
| container_title | Nature biotechnology |
| container_volume | 40 |
| creator | Dolgin, Elie |
| description | Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes. |
| doi_str_mv | 10.1038/s41587-022-01246-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2633895827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2633895827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-aaaa9594fc779c69f143c7f84c133c20a46a50db81851f08593f0dc2c20102433</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gAdZ8CLI6uQ7OUr9hIIXPYc0zerWdrcmuy3-e7NuVfDgXGbC-8yb4UXoGMMFBqouI8NcyRwIyQETJvLNDhpingYstNhNM3Qy5mKADmKcA4BgQuyjAeUES0XFEJ1fl3bqGx8z5xeLrHn1wa7K9Gzsm8_82sZy7TPrmrKuDtFeYRfRH237CD3f3jyN7_PJ493D-GqSOyp5k9tUmmtWOCm1E7rAjDpZKOYwpY6AZcJymE0VVhwXoLimBcwcSRIGwigdobPedxXq99bHxizL2J1nK1-30RBBqdJcEZnQ0z_ovG5Dla5LFAOuJcU8UaSnXKhjDL4wq1AubfgwGEwXpemjNClK8xWl2aSlk611O1362c_Kd3YJoD0Qk1S9-PD79z-2nxkLfJQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640597315</pqid></control><display><type>article</type><title>Diabetes cell therapies take evasive action</title><source>MEDLINE</source><source>Nature</source><source>SpringerLink Journals - AutoHoldings</source><creator>Dolgin, Elie</creator><creatorcontrib>Dolgin, Elie</creatorcontrib><description>Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/s41587-022-01246-w</identifier><identifier>PMID: 35217836</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Agriculture ; Bioinformatics ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Cell therapy ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - therapy ; Evasive actions ; Genetic modification ; Humans ; Life Sciences ; News Feature ; Stem cells</subject><ispartof>Nature biotechnology, 2022-03, Vol.40 (3), p.291-295</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. corrected publication 2022</rights><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. corrected publication 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-aaaa9594fc779c69f143c7f84c133c20a46a50db81851f08593f0dc2c20102433</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41587-022-01246-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41587-022-01246-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35217836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dolgin, Elie</creatorcontrib><title>Diabetes cell therapies take evasive action</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.</description><subject>Agriculture</subject><subject>Bioinformatics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cell therapy</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - therapy</subject><subject>Evasive actions</subject><subject>Genetic modification</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>News Feature</subject><subject>Stem cells</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1LAzEQhoMotlb_gAdZ8CLI6uQ7OUr9hIIXPYc0zerWdrcmuy3-e7NuVfDgXGbC-8yb4UXoGMMFBqouI8NcyRwIyQETJvLNDhpingYstNhNM3Qy5mKADmKcA4BgQuyjAeUES0XFEJ1fl3bqGx8z5xeLrHn1wa7K9Gzsm8_82sZy7TPrmrKuDtFeYRfRH237CD3f3jyN7_PJ493D-GqSOyp5k9tUmmtWOCm1E7rAjDpZKOYwpY6AZcJymE0VVhwXoLimBcwcSRIGwigdobPedxXq99bHxizL2J1nK1-30RBBqdJcEZnQ0z_ovG5Dla5LFAOuJcU8UaSnXKhjDL4wq1AubfgwGEwXpemjNClK8xWl2aSlk611O1362c_Kd3YJoD0Qk1S9-PD79z-2nxkLfJQ</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Dolgin, Elie</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20220301</creationdate><title>Diabetes cell therapies take evasive action</title><author>Dolgin, Elie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-aaaa9594fc779c69f143c7f84c133c20a46a50db81851f08593f0dc2c20102433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Agriculture</topic><topic>Bioinformatics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cell therapy</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - therapy</topic><topic>Evasive actions</topic><topic>Genetic modification</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>News Feature</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dolgin, Elie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dolgin, Elie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diabetes cell therapies take evasive action</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>40</volume><issue>3</issue><spage>291</spage><epage>295</epage><pages>291-295</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>35217836</pmid><doi>10.1038/s41587-022-01246-w</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2022-03, Vol.40 (3), p.291-295 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2633895827 |
| source | MEDLINE; Nature; SpringerLink Journals - AutoHoldings |
| subjects | Agriculture Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Cell therapy Diabetes Diabetes mellitus Diabetes Mellitus - therapy Evasive actions Genetic modification Humans Life Sciences News Feature Stem cells |
| title | Diabetes cell therapies take evasive action |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A01%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diabetes%20cell%20therapies%20take%20evasive%20action&rft.jtitle=Nature%20biotechnology&rft.au=Dolgin,%20Elie&rft.date=2022-03-01&rft.volume=40&rft.issue=3&rft.spage=291&rft.epage=295&rft.pages=291-295&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/s41587-022-01246-w&rft_dat=%3Cproquest_cross%3E2633895827%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640597315&rft_id=info:pmid/35217836&rfr_iscdi=true |